On July 29, 2024, GSK plc announced a confidential settlement in the Zantac (ranitidine) case involving Ronald Kimbrow, with no admission of liability. GSK will continue to defend itself vigorously as scientific studies indicate there's no reliable evidence linking ranitidine to cancer risk.